ReviewDeutsches Arzteblatt international2011
The morphological and molecular diagnosis of lung cancer.
Review in Deutsches Arzteblatt international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 63 citations in OpenAlex.
- Occupational benzene exposure and risk of lung cancer: a systematic review and meta-analysis.European journal of epidemiology · 2026Review
- Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future.International journal of molecular sciences · 2025Review
- Segmentation of Non-Small Cell Lung Carcinomas: Introducing DRU-Net and Multi-Lens Distortion.Journal of imaging · 2025Article
- Representation of high-dimensional cell morphology and morphodynamics in 2D latent space.Physical biology · 2025Article
- Article
- Characterization of Nonsmall Cell Lung Carcinoma in Limited Biopsy Samples and Identifying Optimal Immunohistochemical Marker Combinations in Resource-Constrained Setup: An Institutional Experience.Avicenna journal of medicine · 2024Article
- Navigating the Frontiers of Machine Learning in Neurodegenerative Disease Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.Pharmaceutics · 2023Review
- Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer.Biomedicines · 2023Review
- Potential predictors of immunotherapy in small cell lung cancer.Pathology oncology research : POR · 2023Review
- Identification of Cigarette Smoking-Related Novel Biomarkers in Lung Adenocarcinoma.BioMed research international · 2022Article
- Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer.Current treatment options in oncology · 2021Review
- Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non-Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study.International journal of general medicine · 2021Article
- Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study.Frontiers in oncology · 2021Article
- Identification of a novel autophagy signature for predicting survival in patients with lung adenocarcinoma.PeerJ · 2021Article
- Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer.Drugs - real world outcomes · 2020Article
- Nano targeted Therapies Made of Lipids and Polymers have Promising Strategy for the Treatment of Lung Cancer.Materials (Basel, Switzerland) · 2020Review
- Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors.Cancer management and research · 2020Review
- Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases.Frontiers in oncology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Germany, lung cancer causes more deaths than any other malignant disease. Its main etiology is smoking, but other risk factors need to be considered as well. The morphological, molecular and biological phenotype is complex and should no longer be just categorized as either small-cell or non-small cell lung cancer.
methodsThis review article is based on the authors' longstanding involvement in the scientific investigation and diagnostic evaluation of lung cancer, including contributions to the current WHO classification and collaboration in the new interdisciplinary classification of adenocarcinoma. The relevant literature was selectively reviewed.
resultsLung cancer is morphologically classified into four main subtypes-small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, and large-cell carcinoma. Genetic and molecular analyses have revealed distinct differences within subtypes; in particular, adenocarcinomas can be further subdivided. Complex techniques of genomic analysis are now available, but clinicopathological data are still the most important determinants of prognosis and are clearly better for this purpose than molecular classification alone. Nonetheless, the assessment of specific molecular markers is becoming increasingly important.
conclusionThe morphological and molecular classification of lung cancer is undergoing a re-evaluation which will lead to more accurate assessment of individual prognoses and to improved prediction of the response to specific treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.